Skip to main content
. Author manuscript; available in PMC: 2010 Oct 7.
Published in final edited form as: N Engl J Med. 2010 Feb 18;362(7):600–613. doi: 10.1056/NEJMoa0904084

Table 1.

Baseline Characteristics of the Study Patients, According to Treatment Group

Characteristic Platelet Dose*
Low
Dose
(N = 417)		 P Value,
Low vs. Medium
Dose		 Medium
Dose
(N = 423)		 P Value,
Medium vs. High
Dose		 High
Dose
(N = 432)		 P Value,
High vs. Low
Dose
Age — yr 0.18 0.20 0.02
  Median 47 50 51
  Interquartile range 30–57 34–58 32–62
Sex — no. (%) 0.44 0.83 0.33
  Male 243 (58) 258 (61) 267 (62)
  Female 174 (42) 165 (39) 165 (38)
Weight — kg 0.34 0.82 0.43
  Median 80 78 78
  Interquartile range 65–92 60–92 63–91
Height — cm 0.31 0.22 0.85
  Median 170 170 170
  Interquartile range 162–178 160–177 161–178
Body-surface area — m2 0.36 0.74 0.54
  Median 1.9 1.9 1.9
  Interquartile range 1.7–2.1 1.6–2.1 1.7–2.1
Previous pregnancy
  No./total no. of women (%) 111/174 (64) 0.09 120/163 (74) 0.11 110/164 (67) 0.69
  No. of pregnancies 0.33 0.97 0.32
    Median 3 2 3
    Interquartile range 2–4 2–4 2–3
Previous transfusion — no. (%)
  Platelets 244 (59) 0.67 240 (57) 0.68 240 (56) 0.40
  Red cells 316 (76) 0.62 326 (77) 0.13 314 (73) 0.32
Spleen status — no. (%) 0.41 0.43 0.75
  Nonpalpable 393 (94) 390 (92) 403 (93)
  Enlarged 15 (4) 18 (4) 20 (5)
  Splenectomized 9 (2) 15 (4) 9 (2)
Primary diagnosis — no. (%) 0.35 0.40 0.45
  Acute leukemia 202 (48) 186 (44) 185 (43)
  Lymphoma 91 (22) 89 (21) 84 (19)
  Myeloma 39 (9) 59 (14) 56 (13)
  Chronic leukemia 24 (6) 24 (6) 33 (8)
  Myelodysplasia 16 (4) 26 (6) 14 (3)
  Solid tumor 5 (1) 6 (1) 7 (2)
  Other 40 (10) 33 (8) 53 (12)
Stratification category — no. (%) 1.00 0.96 0.97
  Allogeneic stem-cell transplantation 173 (41) 173 (41) 177 (41)
  Autologous or syngeneic stem-cell
  transplantation		 138 (33) 142 (34) 149 (34)
   Chemotherapy or radiation (i.e., non-
  transplantation) therapy for
  hematologic cancer		 104 (25) 105 (25) 104 (24)
  Chemotherapy or radiation (i.e., non-
  transplantation) therapy for
  solid tumor		 2 (<1) 3 (1) 2 (<1)
Laboratory values
  Hemoglobin 0.29 0.41 0.78
    No. with data 415 421 432
    Median — g/dl 9.7 9.9 9.8
    Interquartile range — g/dl 9.0–10.7 9.1–10.7 9.0–10.7
  Hematocrit 0.64 0.87 0.76
    No. with data 413 419 431
    Median — % 28.0 28.2 28.0
    Interquartile range — % 26.0–31.0 26.0–31.0 26.0–31.0
  Platelet count 0.43 0.008 0.07
    No. with data 415 421 432
    Median — ×10−3/mm3 39 40 35
    Interquartile range — ×10−3/mm3 25–62 26–66 24–54
  Prothrombin time† 0.79 0.70 0.90
    No. with data 356 369 377
    Median — ×ULN 0.92 0.92 0.92
    Interquartile range — ×ULN 0.85–0.99 0.85–0.99 0.86–0.99
  International normalized ratio 0.83 0.82 0.99
    No. with data 411 419 428
    Median 1.0 1.0 1.1
    Interquartile range 1.0–1.1 1.0–1.1 1.0–1.1
  Partial thromboplastin time 0.64 0.78 0.52
    No. with data 411 419 430
    Median — sec 29.1 29.0 29.0
    Interquartile range — sec 26.6–32.9 26.3–32.2 26.0–32.9
  Fibrinogen 0.89 0.57 0.45
    No. with data 409 417 430
    Median — mg/dl 357 355 369
    Interquartile range — mg/dl 279–459 276–465 283–468
  Positive for panel-reactive antibody 0.97 0.98 0.95
    No. with data 389 391 410
    Median — % of lymphocytes tested 0.0 0.0 0.0
    Interquartile range — % of lympho-
  cytes tested		 0.0–0.0 0.0–0.0 0.0–0.0
*

Platelet doses were as follows: low dose, 1.1×1011 platelets per square meter of body-surface area; medium dose, 2.2×1011 platelets per square meter; and high dose, 4.4×1011 platelets per square meter.

†

ULN denotes upper limit of the normal range.